FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995934717> ?p ?o ?g. }

• W2995934717 endingPage "221" @default.
• W2995934717 startingPage "207" @default.
• W2995934717 abstract "Background Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma. We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study. Methods DREAMM-2 is an open-label, two-arm, phase 2 study done at 58 multiple myeloma specialty centres in eight countries. Patients (aged ≥18 years) with relapsed or refractory multiple myeloma with disease progression after three or more lines of therapy and who were refractory to immunomodulatory drugs and proteasome inhibitors, and refractory or intolerant (or both) to an anti-CD38 monoclonal antibody with an Eastern Cooperative Oncology Group performance status of 0–2 were recruited, centrally randomly assigned (1:1) with permuted blocks (block size 4), and stratified by previous lines of therapy (≤4 vs >4) and cytogenetic features to receive 2·5 mg/kg or 3·4 mg/kg belantamab mafodotin via intravenous infusion every 3 weeks on day 1 of each cycle until disease progression or unacceptable toxicity. The intention-to-treat population comprised all randomised patients, regardless of treatment administration. The safety population comprised all patients who received at least one dose of belantamab mafodotin. The primary outcome was the proportion of randomly assigned patients in the intention-to-treat population who achieved an overall response, as assessed by an independent review committee. This study is registered with ClinicalTrials.gov, NCT03525678, and is ongoing. Findings Between June 18, 2018, and Jan 2, 2019, 293 patients were screened and 196 were included in the intention-to-treat population (97 in the 2·5 mg/kg cohort and 99 in the 3·4 mg/kg cohort). As of June 21, 2019 (the primary analysis data cutoff date), 30 (31%; 97·5% CI 20·8–42·6) of 97 patients in the 2·5 mg/kg cohort and 34 (34%; 23·9–46·0) of 99 patients in the 3·4 mg/kg cohort achieved an overall response. The most common grade 3–4 adverse events in the safety population were keratopathy (in 26 [27%] of 95 patients in the 2·5 mg/kg cohort and 21 [21%] of 99 patients in the 3·4 mg/kg cohort), thrombocytopenia (19 [20%] and 33 [33%]), and anaemia (19 [20%] and 25 [25%]); 38 (40%) of 95 patients in the 2·5 mg/kg cohort and 47 (47%) of 99 in the 3·4 mg/kg cohort reported serious adverse events. Two deaths were potentially treatment related (one case of sepsis in the 2·5 mg/kg cohort and one case of haemophagocytic lymphohistiocytosis in the 3·4 mg/kg cohort). Interpretation Single-agent belantamab mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma. Funding GlaxoSmithKline." @default.
• W2995934717 created "2019-12-26" @default.
• W2995934717 creator A5006108161 @default.
• W2995934717 creator A5011827756 @default.
• W2995934717 creator A5016941619 @default.
• W2995934717 creator A5018048721 @default.
• W2995934717 creator A5022520524 @default.
• W2995934717 creator A5022522496 @default.
• W2995934717 creator A5023276777 @default.
• W2995934717 creator A5023508449 @default.
• W2995934717 creator A5023624767 @default.
• W2995934717 creator A5024315315 @default.
• W2995934717 creator A5025168585 @default.
• W2995934717 creator A5026648113 @default.
• W2995934717 creator A5026740596 @default.
• W2995934717 creator A5027311948 @default.
• W2995934717 creator A5030746256 @default.
• W2995934717 creator A5031690184 @default.
• W2995934717 creator A5042432109 @default.
• W2995934717 creator A5043526996 @default.
• W2995934717 creator A5046804125 @default.
• W2995934717 creator A5047778089 @default.
• W2995934717 creator A5048362577 @default.
• W2995934717 creator A5048618968 @default.
• W2995934717 creator A5052787074 @default.
• W2995934717 creator A5053731124 @default.
• W2995934717 creator A5064710410 @default.
• W2995934717 creator A5065834452 @default.
• W2995934717 creator A5071438752 @default.
• W2995934717 creator A5077110117 @default.
• W2995934717 creator A5080959881 @default.
• W2995934717 creator A5081566117 @default.
• W2995934717 creator A5082564837 @default.
• W2995934717 creator A5082712392 @default.
• W2995934717 creator A5083639923 @default.
• W2995934717 creator A5084492085 @default.
• W2995934717 creator A5086481435 @default.
• W2995934717 creator A5089853890 @default.
• W2995934717 creator A5091215609 @default.
• W2995934717 creator A5091396091 @default.
• W2995934717 date "2020-02-01" @default.
• W2995934717 modified "2023-10-17" @default.
• W2995934717 title "Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study" @default.
• W2995934717 cites W1982877913 @default.
• W2995934717 cites W1987390357 @default.
• W2995934717 cites W2100545964 @default.
• W2995934717 cites W2202939373 @default.
• W2995934717 cites W2414278460 @default.
• W2995934717 cites W2422962677 @default.
• W2995934717 cites W2486629951 @default.
• W2995934717 cites W2532841680 @default.
• W2995934717 cites W2555849466 @default.
• W2995934717 cites W2688500010 @default.
• W2995934717 cites W2765175017 @default.
• W2995934717 cites W2798140657 @default.
• W2995934717 cites W2799813088 @default.
• W2995934717 cites W2807637103 @default.
• W2995934717 cites W2875569594 @default.
• W2995934717 cites W2900068404 @default.
• W2995934717 cites W2901760736 @default.
• W2995934717 cites W2906581363 @default.
• W2995934717 cites W2921533600 @default.
• W2995934717 cites W2923666301 @default.
• W2995934717 cites W2924578117 @default.
• W2995934717 cites W2943335541 @default.
• W2995934717 cites W2952039293 @default.
• W2995934717 cites W2969931905 @default.
• W2995934717 doi "https://doi.org/10.1016/s1470-2045(19)30788-0" @default.
• W2995934717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31859245" @default.
• W2995934717 hasPublicationYear "2020" @default.
• W2995934717 type Work @default.
• W2995934717 sameAs 2995934717 @default.
• W2995934717 citedByCount "501" @default.
• W2995934717 countsByYear W29959347172020 @default.
• W2995934717 countsByYear W29959347172021 @default.
• W2995934717 countsByYear W29959347172022 @default.
• W2995934717 countsByYear W29959347172023 @default.
• W2995934717 crossrefType "journal-article" @default.
• W2995934717 hasAuthorship W2995934717A5006108161 @default.
• W2995934717 hasAuthorship W2995934717A5011827756 @default.
• W2995934717 hasAuthorship W2995934717A5016941619 @default.
• W2995934717 hasAuthorship W2995934717A5018048721 @default.
• W2995934717 hasAuthorship W2995934717A5022520524 @default.
• W2995934717 hasAuthorship W2995934717A5022522496 @default.
• W2995934717 hasAuthorship W2995934717A5023276777 @default.
• W2995934717 hasAuthorship W2995934717A5023508449 @default.
• W2995934717 hasAuthorship W2995934717A5023624767 @default.
• W2995934717 hasAuthorship W2995934717A5024315315 @default.
• W2995934717 hasAuthorship W2995934717A5025168585 @default.
• W2995934717 hasAuthorship W2995934717A5026648113 @default.
• W2995934717 hasAuthorship W2995934717A5026740596 @default.
• W2995934717 hasAuthorship W2995934717A5027311948 @default.
• W2995934717 hasAuthorship W2995934717A5030746256 @default.
• W2995934717 hasAuthorship W2995934717A5031690184 @default.
• W2995934717 hasAuthorship W2995934717A5042432109 @default.
• W2995934717 hasAuthorship W2995934717A5043526996 @default.
• W2995934717 hasAuthorship W2995934717A5046804125 @default.
• W2995934717 hasAuthorship W2995934717A5047778089 @default.

• next